Yes — on July 13, 2026, the FDA approved once-weekly subcutaneous Leqembi Iqlik as a starting dose for early Alzheimer's disease. Read the headline as at-home initiation, not broader eligibility or lower risk. Leqembi is lecanemab-irmb, an antibody drug that clears amyloid plaques linked to Alzheimer's. Early disease here means mild cognitive impairment or mild dementia due to Alzheimer's.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official notice from Biospace — Use this primary source to verify the official announcement.
- Read the official notice from Eisai — Use this primary source to verify the official announcement.
Table of Contents
- Who can consider a home start?
- What changes with day-one subcutaneous dosing?
- What safety checks still apply?
- What should patients do next?
Who can consider a home start?
The at-home start is only for adults with early-stage symptoms tied to Alzheimer's. Treatment begins only after tests confirm amyloid in the brain. That confirmation step still gates access.
A memory-clinic diagnosis alone is not enough. As Eisai and Biogen explained in their July approval announcement, amyloid must be verified before the first dose. Ask whether your stage, test results, and other health issues fit the label. Families should also weigh who can help with weekly injections, storage, and follow-up visits.
What changes with day-one subcutaneous dosing?
The new start is 500 mg once weekly, given as two back-to-back 250-mg autoinjector shots at home. Patients can then stay on subcutaneous dosing or switch between IV and subcutaneous forms. That removes the old sequence of 18 months of biweekly IV infusions before home dosing, according to NeurologyLive's dosing report.
Weekly 360-mg home maintenance had been approved Aug. 29, 2025, but only after IV induction. The practical gain is location and schedule, not a different disease target. FDA bridging compared blood exposure, amyloid clearance, benefit, and safety between the shot and IV, using Clarity AD and extension data.
What safety checks still apply?
Leqembi carries a boxed warning for amyloid-related imaging abnormalities, called ARIA. ARIA-E means brain swelling or fluid. ARIA-H means small bleeds or surface iron deposits. Eisai and Biogen recommend ApoE epsilon-4 gene testing before treatment.
Clinics also obtain a baseline MRI and repeat scans on schedule to catch ARIA early. A home first dose does not make monitoring home-based. Report headache, confusion, dizziness, vision change, nausea, or gait trouble promptly. Do not skip scans because injections feel routine.
What should patients do next?
Eisai planned U.S. availability for Aug. 24-27, 2026, according to the Alzheimer's Drug Discovery Foundation statement.
The group called it the first anti-amyloid therapy patients can start at home. Use the wait to prepare concrete questions for your dementia specialist: Bring a medication list, prior brain scans, allergy history, and caregiver availability to that visit. Confirm who teaches injection technique and who covers after-hours symptoms.
- Is my syndrome MCI or mild dementia due to Alzheimer's with confirmed amyloid?
- What is my ApoE epsilon-4 result and MRI plan for ARIA?
- Can our home handle weekly dual injections, refills, and urgent evaluation?
You Might Also Like
- PrecivityAD2 and Younger-Onset Alzheimer’s Diagnosis in 2026: How Younger-Onset Alzheimer’s Families Can Compare Testing Options
- MRI and ARIA Monitoring With At-Home Leqembi in 2026: Follow-Up Decisions People With Early Alzheimer’s May Need to Revisit
- At-Home Leqembi vs IV Infusions After the 2026 FDA Decision: Follow-Up Decisions People With Early Alzheimer’s May Need to Revisit
